On June 5, 2018 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, reported that positive data from the SL-701 and SL-801 clinical trials were presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, IL (Press release, Stemline Therapeutics, JUN 5, 2018, View Source [SID1234527186]). The presentations are available on Stemline’s website (www.stemline.com) under the Scientific Presentations tab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SL-701 – Clinical Highlights

The Phase 2 trial of SL-701 in previously treated GBM patients met its primary endpoint of 12-month overall survival (OS-12)

Long-term survivors: 50% OS-12 with SL-701 + bevacizumab

Major responses, including complete responses (CRs), in second-line GBM

Well-tolerated, with very manageable side effect profile

Long-term survivors were comprised largely of patients with target-specific CD8+ T-cell responses

Median OS of target-specific CD8+ T cell responders not reached

Given the major unmet medical need in GBM and promising safety and efficacy data generated to date with SL-701 + bevacizumab, Stemline is considering next steps including leveraging potential immune-related biomarker in registration-directed trial designs
SL-801 – Clinical Highlights

Manageable safety and tolerability profile, largely grade 1-2 adverse events (AEs), to date
Multiple cases of stable disease (SD) in a heavily pretreated solid tumor patient population
Pharmacokinetic (PK) analyses suggest dose-dependent increases in exposure
Ideal therapeutic dose not yet determined as dose escalation continues
Ivan Bergstein, M.D., Stemline’s CEO, commented, "Our BPDCN disease awareness campaign is kicking into high gear as we approach the end of ASCO (Free ASCO Whitepaper), and we believe that our key messages around BPDCN and CD123 are resonating. Our SL-401 regulatory and pre-launch activities continue to progress, and our timelines remain on track." Dr. Bergstein continued, "Additionally, our SL-701 and SL-801 clinical presentations were very well-received at the conference, and our investigators are excited and engaged. The SL-701 + bevacizumab combination has been well-tolerated and has shown activity, including the emergence of long-term survivors comprised largely of target-specific CD8+ T cell responders. Given the major unmet medical need in GBM and SL-701’s promising safety and efficacy data, we are considering next steps, including applying these immune data in registration-directed trial designs. Additionally, we are encouraged by SL-801’s tolerability profile as we continue to dose escalate in a heavily pretreated solid tumor patient population of unmet medical need. Enrollment is ongoing, and we look forward to further updates later this year."

On June 5, 2018 Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) reported that the company will present at the following conferences in June (Press release, Portola Pharmaceuticals, JUN 5, 2018, View Source;p=RssLanding&cat=news&id=2353383 [SID1234527184]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018, at 9:20 a.m. Pacific Time in Rancho Palos Verdes, CA.

William Blair 38th Annual Growth Stock Conference on Wednesday, June 13, 2018, at 12:40 p.m. Central Time in Chicago, IL.
Both presentations will be webcast live and available for replay from Portola’s website at www.portola.com in the Investor Relations section.

On June 5, 2018 LabCorp (NYSE: LH) reported it will participate at the 38th Annual William Blair Growth Stock Conference (Press release, LabCorp, JUN 5, 2018, View Source;p=RssLanding&cat=news&id=2353390 [SID1234527182]). LabCorp’s presentation is planned for Tuesday, June 12, 2018 at 12:10 PM (CT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.

On June 5, 2018 Jounce Therapeutics, Inc. (the "Company") conducted meetings with investors attending the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois (Presentation, Jounce Therapeutics, JUN 5, 2018, View Source [SID1234527180]). As part of these meetings, the Company delivered the slide presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 5, 2018 Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, reported the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research (Press release, Endocyte, JUN 5, 2018, View Source [SID1234527177]). The international, prospective, open-label, multicenter, randomized phase 3 study is evaluating patients with progressive prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have received at least one novel androgen axis drug (abiraterone or enzalutamide) and at least one taxane regimen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the initiation of this important clinical trial so quickly following our end-of-phase 2 meeting with the FDA. This speed of execution is a result of the enthusiasm of participating physicians and the focus and urgency of our clinical operations team," said Mike Sherman, president and CEO of Endocyte. "Having collaborated with several of the key opinion leaders in prostate cancer around the world, we are confident in the robustness of the VISION trial design and eager to complete enrollment."

"In spite of the introduction of new drugs in the last several years, there continues to be a significant need for therapeutic alternatives with new mechanisms of action for men suffering from metastatic castration-resistant prostate cancer," said Oliver Sartor, M.D., Medical Director of the Tulane Cancer Center. "The data generated with 177Lu-PSMA-617 in early clinical trials have yielded a high level of enthusiasm among physicians. There is a real need to advance this investigational therapy as quickly as possible for these heavily pre-treated patients and begin the work to evaluate it in earlier lines of therapy, particularly in advance of chemotherapy."

Phase 2 Clinical Data Presented at ASCO (Free ASCO Whitepaper)

Incremental data from an expansion cohort of 20 patients recently presented at ASCO (Free ASCO Whitepaper) confirmed and improved upon PSA response to 177Lu-PSMA-617 previously reported in a cohort of 30 patients enrolled in a phase 2 trial at the Peter MacCallum Cancer Centre in Melbourne, Australia.

"Twenty-six of the 50 patients (52%) enrolled in this trial are more heavily pre-treated than the minimum eligibility criteria for the VISION trial, so it is particularly compelling to see a PSA decline of 50% or more in 62% of these advanced patients and a median PSA progression-free survival (PFS) of 7.0 months," said Alison Armour, chief medical officer of Endocyte. "While the overall survival data are not yet mature for the second cohort of 20 patients, we were pleased to see six-month survival rates similar to the first cohort of 30 patients. Consistent response rates across patient groups with variations in prior therapy is likely a result of a potential differentiated mechanism of action for 177Lu-PSA-617 compared to currently approved therapies."

177Lu-PSMA-617 was generally well tolerated, with no significant dose-limiting toxicities observed. The most common treatment-related toxicity was Grade 1-2 xerostomia (dry mouth) seen in 68% of patients, but infrequently required any intervention. The occurrence of treatment-related Grade 3-4 hematologic toxicity was low and comparable to the largest retrospective published cohort.

VISION Phase 3 Trial Design

VISION will enroll up to 750 patients worldwide with PSMA-positive scans, randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 plus best supportive/best standard of care versus best supportive/best standard of care alone. Best supportive/best standard of care is palliative in nature and, at the discretion of the investigator, may include enzalutamide or abiraterone. Patients treated with 177Lu-PSMA-617 will receive 7.4 gigabecquerel (GBq) intravenously every six weeks for a maximum of six cycles.

The primary endpoint of the study agreed to by the FDA is overall survival (OS). Secondary endpoints include radiographic progression-free survival (rPFS), response evaluation criteria in solid tumors (RECIST) response, and time to first symptomatic skeletal event. Two interim efficacy analyses of OS will be conducted at 50% and 70% of the first 489 targeted events. Endocyte plans to discuss modifying the first interim analysis endpoint to rPFS to expedite a potential accelerated approval in the U.S. Further information on the global Phase 3 VISION study can be found at www.VISIONClinicalTrial.com.

Website Information

Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the "Investors & News" section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the "Investors & News" section of Endocyte’s website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.